title: Non-surgical septal myocardial reduction by coil embolization for hypertrophic obstructive cardiomyopathy: early and 6 months follow-up.
abstract: OBJECTIVE
  To evaluate the feasibility and the incidence of complete heart block (CHB) after non-surgical septal myocardial reduction by coil embolization in hypertrophic obstructive cardiomyopathy (HOCM).
  
  
  RESULTS
  Twenty patients with HOCM and drug-refractory symptoms underwent non-surgical myocardial septal reduction by coil embolization with detachable coils. Occlusion of septal perforator branches was successfully performed in all patients. We detected neither ventricular tachycardia nor CHB. One patient presented an interventricular septal defect after the procedure, and died 19 days later. Cardiac magnetic resonance imaging showed, in all patients, an increase in areas of hyperenhancement in the interventricular septum (IVS) compared with baseline. At 6-month follow-up, NYHA functional class and peak oxygen consumption were significantly improved compared with baseline (14.8 +/- 4.5 vs. 18.5 +/- 4.5 mL/kg/min; P = 0.001, respectively). Echocardiography showed a significant reduction of the IVS thickness and left ventricular outflow tract gradient (21 +/- 3 vs. 17 +/- 4 mm, P < 0.0001; 80 +/- 29 to 35 +/- 29 mmHg, P < 0.0001, respectively).
  
  
  CONCLUSIONS
  The results of this pilot non-randomized study suggest that non-surgical septal myocardial reduction by coil embolization in HOCM is feasible and does not induce CHB. Larger studies, ideally with a randomized comparison between coil embolization and alcohol septal ablation, are warranted.
authors.affiliation: Service de Cardiologie, AP-HP, Hôpital Européen Georges Pompidou, Université Paris-Descartes, Faculté de Médecine, Unité INSERM U849, Paris, France.
authors.forename: Eric
authors.initials: E
authors.lastname: Durand
authors.forename: Elie
authors.initials: E
authors.lastname: Mousseaux
authors.forename: Pierre
authors.initials: P
authors.lastname: Coste
authors.forename: Rémy
authors.initials: R
authors.lastname: Pillière
authors.forename: Olivier
authors.initials: O
authors.lastname: Dubourg
authors.forename: Ludovic
authors.initials: L
authors.lastname: Trinquart
authors.forename: Gilles
authors.initials: G
authors.lastname: Chatellier
authors.forename: Albert
authors.initials: A
authors.lastname: Hagège
authors.forename: Michel
authors.initials: M
authors.lastname: Desnos
authors.forename: Antoine
authors.initials: A
authors.lastname: Lafont
mesh_terms: D000368:Aged; D002312:Cardiomyopathy, Hypertrophic / Q000175:diagnosis / Q000628:therapy*; D017115:Catheter Ablation / Q000009:adverse effects / Q000379:methods*; D015331:Cohort Studies; D003287:Contrast Media; D003331:Coronary Vessels; D004621:Embolization, Therapeutic / Q000009:adverse effects / Q000295:instrumentation / Q000379:methods*; D005080:Exercise Test; D005240:Feasibility Studies; D005260:Female; D006327:Heart Block / Q000453:epidemiology*; D006346:Heart Septum; D006801:Humans; D008297:Male; D008875:Middle Aged; D010865:Pilot Projects; D015607:Stents; D016896:Treatment Outcome
chemical_list: D003287:Contrast Media